Atrium Therapeutics, Inc. (RNA)
| Market Cap | 140.44M-43.7% |
| Revenue (ttm) | 35.84M |
| Net Income | -65.99M |
| EPS | -5.44 |
| Shares Out | 17.11M |
| PE Ratio | n/a |
| Forward PE | -1.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,599 |
| Open | 8.15 |
| Previous Close | 7.93 |
| Day's Range | 8.00 - 8.23 |
| 52-Week Range | 7.63 - 16.77 |
| Beta | n/a |
| Analysts | none |
| Price Target | 25.00(+204.51%) |
| Earnings Date | Nov 9, 2026 |
Insiders here have filed 8 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About RNA
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
$RNA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RNA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RNA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RNA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RNA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RNA from public contracts
Source: USAspending.gov
RNA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RNA’s recent data — informational, not investment advice